OTC/ Consumer Health market in France with the most important distributors and importers

Table of Contents

1. Executive Summary......................................................................................................................................3

2. Market Definition and Scope.........................................................................................................................3

3. Market Volume and Trends........................................................................................................................... 4

3.1 Market size............................................................................................................................................4

3.2 Long-term development.........................................................................................................................4

3.3 Key trends.............................................................................................................................................. 4

4. Distribution Structure....................................................................................................................................5

4.1 Pharmacy channel................................................................................................................................. 5

4.2 Other channels......................................................................................................................................5

5. Major Market Players....................................................................................................................................5

5.1 Manufacturers and brand owners..........................................................................................................5

5.2 Wholesalers and pharmacy groups.......................................................................................................6

6. Market Opportunities for Foreign Suppliers.................................................................................................. 6

6.1 Branded products.................................................................................................................................. 6

6.2 Private label / No-name.........................................................................................................................6

6.3 Success factors.....................................................................................................................................7

7. Products and Product Groups with Good Sales Prospects...........................................................................7

8. Market Access Requirements....................................................................................................................... 8

8.1 Requirements applying to all suppliers..................................................................................................8

8.2 Suppliers from the EU / EEA..................................................................................................................8

8.3 Suppliers from non-EU Europe (e.g., Switzerland, United Kingdom, Turkey, Serbia, Ukraine).............9

8.4 Suppliers from outside Europe (e.g., USA, Asia, Latin America, Middle East).......................................9

8.5 Overview by origin.................................................................................................................................9

9. Market Entry Strategy and Practical Recommendations.............................................................................10

10. Directory of Importers and Distribution Partners.......................................................................................10

10.1 Pharmaceutical Full-Line Wholesalers (Grossistes-Répartiteurs)......................................................10

10.2 Pharmacy Groups and Central Purchasing (CAP/SRA) – incl. Own-Brand Programmes..................12

10.3 OTC / Pharma Importers, Exploitants and In-Licensing Partners......................................................14

10.4 Supermarket Central Purchasing and Discounters............................................................................16

10.5 Organic and Natural Health Retailers................................................................................................17

10.6 Online Pharmacies and Health & Beauty E-Retailers........................................................................18

10.7 FMCG and Full-Range Non-Food Importers......................................................................................19

10.8 Useful Institutions and Trade Bodies.................................................................................................19

11. How to Approach French Partners............................................................................................................ 19

12. Sources and Methodology........................................................................................................................20

1. Executive Summary

France is one of Europe's largest self-care markets, but also one of its most regulated. Non-prescription medicines may only be sold in pharmacies (including the online shops of pharmacies), and almost the entire pharmacy self-care segment – OTC medicines, food supplements and consumer medical devices – is sold through roughly 20,000 community pharmacies supplied by a handful of full-line wholesalers and organised in purchasing groups. In 2025 the pharmacy "first-line" market (produits de premier recours: non-prescription medicines, food supplements and consumer medical devices, measured at consumer prices) reached €4.74 bn (+2 %). Growth is driven almost entirely by food supplements (€1.65 bn, +5.1 %), while OTC medicines are flat (+0.2 %) and consumer medical devices grow slowly (€0.90 bn, +0.9 %). Across all channels the food-supplement market passed €3 bn for the first time in 2025, with pharmacies accounting for about 55 % of sales. Key conclusions for foreign suppliers: • Medicines (OTC drugs) require a marketing authorisation and a French or EU-based pharmaceutical "exploitant". For most foreign manufacturers the realistic routes are out-licensing or distribution agreements with French OTC laboratories (e.g., Cooper, Mayoly, Genevrier, Gilbert, Perrigo France) or the decentralised/mutual-recognition procedure with a local partner. • Food supplements, medical devices and dermocosmetics offer the fastest entry: no marketing authorisation, but French declaration/notification, French labelling and EU-compliant formulations are mandatory. • Private label is a real opportunity: pharmacy groups (Giphar, Lafayette/Hygie31, Pharmabest, Aprium) and wholesalers are expanding own-brand ranges, while supermarkets and discounters source private-label supplements and hygiene products by tender. • Best prospects: sleep/stress and mood supplements, immunity and vitality, digestion/probiotics, women's health (menopause, fertility), joint health, natural and organic formulations, saline/ENT and dry-eye medical devices, dermocosmetics for sensitive skin and sun care. • Market access differs sharply by origin: EU/EEA suppliers benefit from free movement and mutual recognition; suppliers from non-EU Europe (Switzerland, UK, Turkey, Western Balkans, Ukraine) and from outside Europe need an EU-based responsible party (importer, EU Responsible Person, Authorised Representative, Qualified Person release) and must clear customs and border controls.